Low myocardial protein kinase G activity in heart failure with preserved ejection fraction

Circulation

Volumn 126, Issue 7, 2012, Pages 830-839

  Van Heerebeek, Loek ^a   Hamdani, Nazha ^a   Falcão Pires, Inês ^b   Leite Moreira, Adelino F ^b   Begieneman, Mark P V ^a   Bronzwaer, Jean G F ^a   Van Der Velden, Jolanda ^a   Stienen, Ger J M ^a   Laarman, Gerrit J ^c   Somsen, Aernout ^d   Verheugt, Freek W A ^d   Niessen, Hans W M ^a   Paulus, Walter J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF PORTO   (Portugal)

^c CPRLab   (Netherlands)

^d Onze Lieve Vrouwe Gasthuis ^*  (Netherlands)

Author keywords

diastole; heart failure; muscle cells; natriuretic peptides; nitric oxide

Indexed keywords

3 NITROTYROSINE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CYCLIC GMP DEPENDENT PROTEIN KINASE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN;

ADULT; AORTA STENOSIS; ARTICLE; CELL SIZE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; ENZYME ACTIVITY; FEMALE; HEART EJECTION FRACTION; HEART FAILURE; HEART MUSCLE; HEART MUSCLE BIOPSY; HEART MUSCLE CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; NITROSATIVE STRESS; OBESITY; OXIDATIVE STRESS; PRESERVED EJECTION FRACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE STUDY;

AORTIC VALVE STENOSIS; BIOPSY; COHORT STUDIES; COMORBIDITY; CYCLIC GMP; CYCLIC GMP-DEPENDENT PROTEIN KINASES; DIABETES MELLITUS; FEMALE; HEART; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MYOCARDIUM; NATRIURETIC PEPTIDE, BRAIN; OBESITY; OXIDATIVE STRESS; STROKE VOLUME; TYROSINE;

EID: 84865209443     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.076075     Document Type: Article

References (45)

1. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251-259. (Pubitemid 44079340)
2. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis and treatment. Eur Heart J. 2011;32: 670-679.
3. Paulus WJ, v Ballegoij JJM. Treatment of heart failure with normal ejection fraction: an inconvenient truth! J Am Coll Cardiol. 2010;55: 526-537.
4. Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure-abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med. 2004;350:1953-1959.
5. Selby DE, Palmer BM, LeWinter MM, Meyer M. Tachycardia-induced diastolic dysfunction and resting tone in myocardium from patients with a normal ejection fraction. J Am Coll Cardiol. 2011;58:147-154.
6. Borbely A, van der Velden J, Papp Z, Bronzwaer JGF, Edes I, Stienen GJ, Paulus WJ. Cardiomyocyte stiffness in diastolic heart failure. Circulation. 2005;111:774-781. (Pubitemid 40250638)
7. van Heerebeek L, Borbely A, Niessen HW, Bronzwaer JG, van der Velden J, Stienen GJ, Linke WA, Laarman GJ, Paulus WJ. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation. 2006;113:1966-1973.
8. Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER, Bedja D, Gabrielson KL, Wang Y, Kass DA. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med. 2005;11:214-222. (Pubitemid 40321358)
9. Bishu K, Hamdani N, Mohammed SF, Krüger M, Ohtani T, Ogut O, Brozovich FV, Burnett JC, Linke WA, Redfield MM. Sildenafil and BNP acutely phosphorylate titin and improve diastolic distensbility in vivo. Circulation. 2011;124:2882-2891.
10. Guazzi M, Vicenzi M, Arena R, Guazzi MD. PDE-5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry and clinical status in patients with stable systolic heart failure: results of a 1-year prospective, randomized, placebo controlled trial. Circ Heart Fail. 2011;4:8-17.
11. Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation. 2011;124: 164-174.
12. Borbely A, Falcao-Pires I, van Heerebeek L, Hamdani N, Edes I, Gavina C, Leite-Moreira AF, Bronzwaer JG, Papp Z, van der Velden J, Stienen GJ, Paulus WJ. Hypophosphorylation of the stiff N2B titin isoform raises cardiomyocyte resting tension in failing human myocardium. Circ Res. 2009;104:780-786.
13. Krüger M, Kötter S, Grützner A, Lang P, Andresen C, Redfield MM, Butt E, dos Remedios CG, Linke WA. Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs. Circ Res. 2009;104:87-94.
14. Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, Marino P, Smiseth OA, De Keulenaer G, Leite-Moreira AF, Borbély A, Edes I, Handoko ML, Heymans S, Pezzali N, Pieske B, Dickstein K, Fraser AG, Brutsaert DL. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007;28:2539-2550. (Pubitemid 47614269)
15. Falcão-Pires I, Hamdani N, Borbély A, Gavina C, Schalkwijk CG, van der Velden J, van Heerebeek L, Stienen GJ, Niessen HW, Leite-Moreira AF, Paulus WJ. Diabetes mellitus worsens diastolic left ventricular dysfunction in aortic stenosis through altered myocardial structure and cardiomyocyte stiffness. Circulation. 2011;124:1151-1159.
16. Schulz E, Jansen T, Wenzel P, Daiber A, Münzel T. Nitric oxide, tetrahydrobiopterin, oxidative stress and endothelial dysfunction in hypertension. Antioxid Redox Signal. 2008;10:1115-1126. (Pubitemid 351451710)
17. Nagendran J, Archer SL, Soliman D, Gurtu V, Moudgil R, Haromy A, St Aubin C, Webster L, Rebeyka IM, Ross DB, Light PE, Dyck JR, Michelakis ED. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation. 2007;116: 238-248. (Pubitemid 47196559)
18. Pokreisz P, Vandenwijngeart S, Bito V, Van den Bergh A, Lenaerts I, Busch C, Marsboom G, Gheysens O, Vermeersch P, Biesmans L, Liu X, Gillijns H, Pellens M, Van Lommel A, Buys E, Schoonjans L, Vanhaecke J, Verbeken E, Sipido K, Herijgers P, Bloch KD, Janssens SP. Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse remodelling after myocardial infarction in mice. Circulation. 2009;119:408-416.
19. Lu Z, Xu X, Hu X, Traverse JH, Zhu G, Fasselt J, Tao Y, Zhang P, dos Remedios C, Pritzker M, Hall JL, Garry DJ, Chen Y. Oxidative stress regulates left ventricular PDE5 expression in the failing heart. Circulation. 2010;121:1474-1483.
20. Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC; for the ADHERE Scientific Advisory Committee and Investigators. Clinical presentation, management, and inhospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function. J Am Coll Cardiol. 2006;47:76-84.
21. McMurray JJV, Carson PE, Komajda M, McKelvie R, Zile MR, Ptaszynska A, Staiger C, Donovan JM, Massie BM. Heart failure with preserved ejection fraction: Clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. Eur J Heart Fail. 2008;10: 149-156. (Pubitemid 351227428)
22. Haass M, Kitzman DW, Anand IS, Miller A, Zile MR, Massie BM, Carson PE. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail. 2011;4:324-331.
23. Russo C, Jin Z, Homma S, Rundek T, Elkind MS, Sacco RL, Di Tullio MR. Effect of obesity and overweight on left ventricular diastolic function. J Am Coll Cardiol. 2011;57:1368-1374.
24. Diamant M, Lamb HJ, Groeneveld Y, Endert EL, Smit JW, Bax JJ, Romijn JA, de Roos A, Radder JK. Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. J Am Coll Cardiol. 2003;42:328-335. (Pubitemid 36851426)
25. van Heerebeek L, Hamdani N, Handoko ML, Falcao-Pires I, Musters RJ, Kupreishvili K, Ijsselmuiden AJ, Schalkwijk CG, Bronzwaer JG, Diamant M, Borbély A, van der Velden J, Stienen GJ, Laarman GJ, Niessen HW, Paulus WJ. Diastolic stiffness of the failing diabetic heart: Importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation. 2008;117:43-51. (Pubitemid 350291180)
26. Paulus WJ, Vantrimpont PJ, Shah AM. Acute effects of nitric oxide on left ventricular relaxation and diastolic distensibility in humans. Assessment by bicoronary sodium nitroprusside infusion. Circulation. 1994;89:2070-2078. (Pubitemid 24142783)
27. Grützner A, Garcia-Manyes S, Kötter S, Badilla CL, Fernandez JM, Linke WA. Modulation of titin-based stiffness by disulfide bonding in the cardiac titin N2-B unique sequence. Biophys J. 2009;97:825-834.
28. Silberman GA, Fan TH, Liu H, Jiao Z, Xiao HD, Lovelock JD, Boulden BM, Widder J, Fredd S, Bernstein KE, Wolska BM, Dikalov S, Harrison DG, Dudley SC Jr. Uncoupled cardiac nitric oxide synthase mediates diastolic dysfunction. Circulation. 2010;121:519-528.
29. Wilson Tang WH, Tong W, Shrestha K, Wang Z, Levison BS, Delfraino B, Hu B, Troughton RW, Klein AL, Hazen SL. Differential effects of arginine methylation on diastolic dysfunction and disease progression in patients with chronic systolic heart failure. Eur Heart J. 2008;29: 2506-2513.
30. Visser M, Paulus WJ, Vermeulen MA, Richir MC, Davids M, Wisselink W, de Mol BA, van Leeuwen PA. The role of asymmetric dimethylarginine and arginine in the failing heart and its vasculature. Eur J Heart Fail. 2010;12:1274-1281.
31. Calderone A, Thaik CM, Takahashi N, Chang DL, Colucci WS. Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growthpromoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest. 1998;101:812-818. (Pubitemid 28096078)
32. Fiedler B, Lohmann SM, Smolenski A, Linnemuller S, Pieske B, Schroder F, Molkentin JD, Drexler H, Wollert KC. Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes. Proc Natl Acad Sci USA. 2002;99: 11363-11368. (Pubitemid 34920931)
33. Zhang M, Takimoto E, Hsu S, Lee DI, Nagayama T, Danner T, Koitabashi N, Barth AS, Bedja D, Gabrielson KL, Wang Y, Kass DA. Myocardial remodeling is controlled by myocyte-targeted gene regulation of phosphodiesterase type 5. J Am Coll Cardiol. 2010;56: 2021-2030.
34. Lukowski R, Rybalkin SD, Loga F, Leiss V, Beavo JA, Hofmann F. Cardiac hypertrophy is not amplified by deletion of cGMP-dependent protein kinase I in cardiomyocytes. Proc Natl Acad Sci USA. 2010;107: 5646-5651.
35. Opie LH, Commerford PJ, Gersh BJ, Pfeffer MA. Controversies in Cardiology 4. Controversies in ventricular remodelling. Lancet. 2006; 367:356-367.
36. Solomon SD, Janardhanan R, Verma A, Bourgoun M, Daley WL, Purkayastha D, Lacourcière Y, Hippler SE, Fields H, Naqvi TZ, Mulvagh SL, Arnold JM, Thomas JD, Zile MR, Aurigemma GP. Valsartan in Diastolic Dysfunction (VALIDD) Investigators. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet. 2007;369:2079-2087. (Pubitemid 46935945)
37. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristiani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH. Effect of vasodilator therapy on mortality in chronic congestive heart failure. N Engl J Med. 1986;314:1547-1552.
38. Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R Jr., Ferdinand K, Taylor M, Adams K, Sabolinski M, Worcel M, Cohn JN; African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049-2057.
39. Kamath SA, Drazner MH, Wynne J, Fonarow GC, Yancy CW. Characteristics and outcomes in African Americans with decompensated heart failure. Arch Intern Med. 2008;168:1152-1158. (Pubitemid 351831397)
40. Hirata K, Adji A, Vlachopoulos C, and O'Rourke MF. Effect of sildenafil on cardiac performance in patients with heart failure. Am J Cardiol. 2005;96:1436-1440. (Pubitemid 41566628)
41. Iwanaga Y, Nishi I, Furuichi S, Noguchi T, Sase K, Kihara Y, Goto Y, Nonogi H. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. J Am Coll Cardiol. 2006;47:742-748. (Pubitemid 43243094)
42. Shuai XX, Chen YY, Lu YX, Su GH, Wang YH, Zhao HL, Han J. Diagnosis of heart failure with preserved ejection fraction: which parameters and diagnostic strategies are more valuable? Eur J Heart Fail. 2011;13:737-741.
43. O'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, Heizer GM, Komajda M, Massie BM, McMurray JJV, Nieminen MS, Reist CJ, Rouleau JL, Swedberg K, Adams Jr KF, Anker SD, Atar D, Battler A, Botero R, Bohidar NR, Butler J, Clausell N, Corbalán R, Costanzo MR, Dahlstrom U, Deckelbaum LI, Diaz R, Dunlap ME, Ezekowitz JA, Feldman D, Felker GM, Fonarow GC, Gennevois D, Gottlieb SS, Hill JA, Hollander JE, Howlett JG, Hudson MP, Kociol RD, Krum H, Laucevicius A, Levy WC, Méndez GF, Metra M, Mittal S, Oh BH, Pereira NL, Ponikowski P, Tang WHW, Tanomsup S, Teerlink JR, Triposkiadis F, Troughton RW, Voors AA, Whellan DJ, Zannad F, Califf RM. Effect of Nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365:32-43.
44. Ramasubbu K, Estep J, White DL, Deswal A, Mann DL. Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J Am Coll Cardiol. 2008;51:415-426.
45. Fukuta H, Sane DC, Brucks S, Little WC. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: A preliminary report. Circulation. 2005;112:357-363. (Pubitemid 41022076)